Air Products and Chemicals Impairment and restructuring remained flat by 0.0% to $938.45M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6485.6%, from $14.25M to $938.45M. Over 2 years (FY 2023 to FY 2025), Impairment and restructuring shows an upward trend with a 291.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels indicate significant operational disruption or strategic realignment, often impacting short-term profitability.
The aggregate expense recognized for asset write-downs and costs associated with restructuring operations, such as facil...
Frequently used by capital-intensive firms to isolate non-recurring costs from core operating performance.
msft_impairment_and_restructuring| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $244.60M | $57.00M | $3.75B |
| YoY Change | — | -76.7% | >999% |